首页> 外文期刊>CNS drugs >Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
【24h】

Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.

机译:透皮卡巴拉汀:皮肤不良事件的处理和文献复习。

获取原文
获取原文并翻译 | 示例
           

摘要

Alzheimer's disease is a chronic neurodegenerative disorder resulting in part from the degeneration of cholinergic neurons in the brain. Rivastigmine, a cholinesterase inhibitor, is commonly used as a treatment for dementia due to its ability to moderate cholinergic neurotransmission; however, treatment with oral rivastigmine can lead to gastrointestinal adverse effects such as nausea and vomiting. Transdermal administration of rivastigmine can minimize these adverse effects by providing continuous delivery of the medication, while maintaining the effectiveness of the oral treatment. While the transdermal form of rivastigmine has been found to have fewer systemic adverse effects compared with the oral form, cutaneous reactions, such as contact dermatitis, can lead to discontinuation of the drug in its transdermal form. Lack of patient compliance with regard to applying the patch to the designated site, applying the patch for the correct length of time or rotating patch application sites increases the risk of cutaneous adverse reactions. This article outlines the diagnosis and management of irritant contact dermatitis and allergic contact dermatitis secondary to transdermal rivastigmine. The large majority of reactions to transdermal patches are of an irritant type, which can be diagnosed clinically by the presence of a pruritic, erythematous, eczematous plaque strictly confined to the borders of the patch. In contrast, an allergic reaction can be differentiated by the presence of vesicles and/or oedema, erythema beyond the boundaries of the transdermal patch and lack of improvement of the lesion 48 hours after removal of the offending treatment. By encouraging the patient to follow a regular rotation schedule for the patch, and using lipid-based emollients for irritant dermatitis and pre- and post-treatment topical corticosteroids for allergic dermatitis, cutaneous reactions can often be alleviated and patients can continue with their medication regimen. Other simple changes to a patient's treatment routine, including minimizing the use of harsh soaps, avoiding recently shaven or damaged areas of skin and carefully removing the patch after use, can help to further decrease the risk of dermatitis development.
机译:阿尔茨海默氏病是一种慢性神经退行性疾病,部分是由于大脑胆碱能神经元变性引起的。 Rivastigmine是一种胆碱酯酶抑制剂,由于它具有调节胆碱能神经传递的能力,因此常被用作痴呆的治疗药物。但是,口服卡巴拉汀的治疗会导致胃肠道不良反应,例如恶心和呕吐。 rivastigmine的透皮给药可通过提供连续的药物递送来最大程度地减少这些不利影响,同时保持口服治疗的有效性。尽管已发现卡巴拉汀的经皮形式与口服形式相比具有较少的全身性不良反应,但皮肤反应(如接触性皮炎)可导致药物以其经皮形式停药。对于将贴剂施加到指定部位,在正确的时间长度上施加贴剂或旋转贴剂施加部位,患者缺乏依从性会增加皮肤不良反应的风险。本文概述了继发性卡巴拉汀继发性刺激性接触性皮炎和过敏性接触性皮炎的诊断和处理。对透皮贴剂的绝大多数反应是刺激性的,可以通过严格限制在贴剂边界的瘙痒,红斑,湿疹斑块的存在来临床诊断。相反,过敏反应可以通过囊泡和/或水肿的存在,超出透皮贴片边界的红斑和在去除有害治疗后48小时病变的缺乏来区分。通过鼓励患者遵循常规的贴片轮换时间表,并使用基于脂质的润肤剂治疗刺激性皮炎,以及使用治疗前后的局部皮质类固醇激素治疗过敏性皮炎,通常可以缓解皮肤反应,患者可以继续接受药物治疗。对患者治疗常规的其他简单更改,包括最大程度地减少使用刺激性肥皂,避免最近刮过或受损的皮肤区域以及在使用后小心地去除贴剂,都可以帮助进一步降低患上皮炎的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号